

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 June 2023 (01.06.2023)



(10) International Publication Number
WO 2023/094830 A1

(51) International Patent Classification:

C07D 213/70 (2006.01) C07D 311/76 (2006.01)
C07D 213/71 (2006.01) C07D 317/62 (2006.01)
C07D 213/85 (2006.01) C07D 333/34 (2006.01)
C07D 231/56 (2006.01) C07D 333/38 (2006.01)
C07D 237/18 (2006.01) C07D 333/62 (2006.01)
C07D 239/38 (2006.01) C07D 401/04 (2006.01)
C07D 241/18 (2006.01) C07D 405/04 (2006.01)
C07D 249/18 (2006.01) C07D 409/04 (2006.01)
C07D 277/36 (2006.01) C07D 413/04 (2006.01)
C07D 277/56 (2006.01) C07D 487/04 (2006.01)
C07D 307/16 (2006.01) C07D 513/04 (2006.01)
C07D 309/08 (2006.01) A61P 25/00 (2006.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/GB2022/053000

(22) International Filing Date:

25 November 2022 (25.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2117127.7 26 November 2021 (26.11.2021) GB

(71) Applicant: **LARIO THERAPEUTICS LIMITED**
[GB/GB]; 137a George Street, Edinburgh EH2 4JY (GB).

(72) Inventors: **STEINHAGEN, Henning**; Sachsenhausener-
strasse 30, 65824 Schwalbach (DE). **PEVARELLO, Pao-
lo**; Piazza San Pietro in Ciel d'Oro 7A, 27100 Pavia (IT).
CATALANI, Maria Pia; Via Cantarane, 44, 37129 Verona
(IT).

(74) Agent: **HGF LIMITED**; 1 City Walk, Leeds, West York-
shire LS11 9DX (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS



(57) Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof wherein Ring A, Ring B, R¹, R², R³ and L are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calcium ion channel Cav 2.3. Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases modulated Cav 2.3, including epilepsy, neurodegenerative conditions such as Parkinson's disease, focal, drug-resistant forms of epilepsy, and other neurological disorders such as developmental and epileptic encephalopathies and Fragile X syndrome.

WO 2023/094830 A1